Monday, December 10, 2020
10am EST / 3pm BST / 4pm CEST
Protein A step optimization: Effect of resin selection and buffer preparation process
Jungmin Oh, Ph.D., Manager, New Product Development
Pranav Vengsarkar, Ph.D., Manager, Process Development
Significant investments have been made in upstream technologies and processes in monoclonal antibody manufacturing, with the goal of increasing upstream yields, including efforts to improve raw material characterisation, add single-use systems, perfusion systems and more precisely controlled bioreactors.
On the downstream side, improvements in throughput have not kept similar pace. Finding efficiencies across downstream processing steps and cost-effectively aligning the productivity of downstream production with upstream yields requires complex analysis and optimization.
This presentation will review how to enhance throughput while removing critical impurities and how alternative methods of buffer management can help reduce facility footprint, labor hours and overall cost-of-goods.
Advance your protein A technology with Avantor
Producing breakthrough treatments requires continual advances in bioprocessing productivity. The new Avantor J.T.Baker® BAKERBOND® PROchievATM recombinant protein A affinity chromatography resin uses a novel, proprietary ligand to provide best-in-class purification in critical protein A chromatography step of mAbs downstream processing.
In performance tests conducted against comparable protein A resins, the BAKERBOND® PROchievA™ resin showed excellent dynamic binding capacity for mAbs and demonstrated improved purification results in Fc-Fusion proteins and other, emerging molecules.
Fill out the form below to learn more about the J.T.Baker® BAKERBOND® PROchievATM resin